NAGENDRAN SUKUMAR sold 15.0% of their position (200K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $892.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/13/2026ACC: 0001665124-26-000011
Director
Since Sep 2020
-200K
Net shares
Net seller
$892.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
19.02K acquired · 219.02K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+19.02K
Price / share
$1.71
Trade value
$32.53K
% of position
1.4%
4/10/2026
1.32M→1.34M
Common Stock
Direct
Shares
−200K
Price / share
$4.46
Trade value
$892K
% of position
15.0%
4/10/2026
1.34M→1.14M
Total
Net shares
−180.98K
Net value
-$859.47K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/10/2026 | M · Option Exercise | +19.02K | $1.71 | $32.53K | 1.4% | 1.32M | 1.34M |
| Common Stock Direct | 4/10/2026 | S · Sale | −200K | $4.46 | $892K | 15.0% | 1.34M | 1.14M |
| Total | −180.98K | -$859.47K | ||||||
Derivative Transactions1
Employee Stock Option (right to buy)
Direct
Converts to
Common Stock
19.02K shares
Shares
−19.02K
Strike price
1.71
Held after
455.92K
Exercisable
—
4/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock19.02K shares | 4/10/2026 | M · Option Exercise | −19.02K | 1.71 | — | 455.92K |